• +1-646-491-9876
    • +91-20-67278686

    Search

    Severe Acute Respiratory Syndrome-Pipeline Review H2 2017

    Severe Acute Respiratory Syndrome-Pipeline Review H2 2017

    • Report Code ID: RW00011022657
    • Category Life Sciences
    • No. of Pages 52
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.

    Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

    Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
    -The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Global Markets Direct Report Coverage
    Severe Acute Respiratory Syndrome (SARS)-Overview
    Severe Acute Respiratory Syndrome (SARS)-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Severe Acute Respiratory Syndrome (SARS)-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Severe Acute Respiratory Syndrome (SARS)-Companies Involved in Therapeutics Development
    3-V Biosciences Inc
    Atriva Therapeutics GmbH
    Autoimmune Technologies LLC
    CEL-SCI Corp
    Fab'entech SA
    GeneCure LLC
    Gilead Sciences Inc
    Nanotherapeutics Inc
    Novavax Inc
    Oncovir Inc
    Phelix Therapeutics LLC
    Protein Sciences Corp
    Severe Acute Respiratory Syndrome (SARS)-Drug Profiles
    ATR-006-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEL-1000-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSW-1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    D-3252-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Inhibit Cathepsin L for Coronaviridae Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FDX-000-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-5734-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ML-188-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for SARS Virus Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Poly-ICLC-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SARS (virus like particle) vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    severe acute respiratory syndrome vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    severe acute respiratory syndrome vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SSYA-10001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TVB-3567-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Severe Acute Respiratory Syndrome-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Severe Acute Respiratory Syndrome (SARS)-Dormant Projects
    Severe Acute Respiratory Syndrome (SARS)-Discontinued Products
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables
    Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by 3-V Biosciences Inc, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Atriva Therapeutics GmbH, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Autoimmune Technologies LLC, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by CEL-SCI Corp, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Fab'entech SA, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by GeneCure LLC, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Gilead Sciences Inc, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Nanotherapeutics Inc, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Novavax Inc, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Oncovir Inc, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Phelix Therapeutics LLC, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Pipeline by Protein Sciences Corp, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Dormant Projects, H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Dormant Projects, H2 2017 (Contd..1), H2 2017
    Severe Acute Respiratory Syndrome (SARS)-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Mechanism of Actions, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    3-V Biosciences Inc
    Atriva Therapeutics GmbH
    Autoimmune Technologies LLC
    CEL-SCI Corp
    Fab'entech SA
    GeneCure LLC
    Gilead Sciences Inc
    Nanotherapeutics Inc
    Novavax Inc
    Oncovir Inc
    Phelix Therapeutics LLC
    Protein Sciences Corp

    Request for Sample

    Report Url https://www.reportsweb.com//severe-acute-respiratory-syndrome-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//severe-acute-respiratory-syndrome-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//severe-acute-respiratory-syndrome-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments